Design, synthesis, molecular docking and biological evaluation of 1,3,5-trisubstituted-1H-pyrazole derivatives as anticancer agents with cell cycle arrest, ERK and RIPK3- kinase activities

• Published in: Bioorganic chemistry Vol. 143; p. 107058
• Main Authors: Boshta, Nader M., Temirak, Ahmed, El-Shahid, Zeinab A., Shafiq, Zahid, Soliman, Ahmed A.F.
• Format: Journal Article
• Language: English
• Published: SAN DIEGO Elsevier Inc 01.02.2024; Elsevier
• Subjects: Anticancer agents; Biochemistry & Molecular Biology; Cell cycle arrest; Chemistry; Chemistry, Organic; ERK; Life Sciences & Biomedicine; Molecular docking; Physical Sciences; Pyrazoles; RIPK3; Science & Technology; Cell cycle arrest; Anticancer agents; RIPK3; Pyrazoles; Molecular docking; ERK; APOPTOSIS; DEATH; BREAST; POTENT; NECROSIS; INFLAMMATION; PROSTATE-CANCER; RESISTANCE; RIP3
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2023.107058

[Display omitted] •ERK and RIPK3 kinase modulators play central roles in cellular processes, especially in diseases like cancer.•Novel 1,3,5-trisubstituted-1H-pyrazole derivatives targeting ERK and RIPK3 kinases.•Cell cycle analysis revealed intriguing results, indicating potential DNA replication phase inhibition.•The results supported by molecular docking studies. The need for new ERK and RIPK3 kinase modulators arises from their central roles in cellular processes, especially in diseases like cancer. This research focused on a ligand-based strategy, incorporating previously documented 1,3,5-trisubstituted-1H-pyrazole derivatives, to craft innovative inhibitors specifically targeting ERK and RIPK3 kinases. Compounds 6, 7, 10a, 10c, and 10d exhibited significant cytotoxicity against PC-3 and MCF-7 cancer cell lines, with IC50 values ranging from 21.9 to 28.6 µM and 3.90–35.5 µM, respectively values surpassing those of the reference compound Doxorubicin. Additionally, cell cycle analysis revealed intriguing results, particularly with 10d inducing cell cycle arrest at the S phase in treated PC-3 cells, indicating potential DNA replication phase inhibition. Moreover, compounds 6, 10a, and 10d exhibited promising results in the in vitro kinase assay supported by molecular docking studies. The core scaffold of these compounds established interactions with vital amino acids within the active pockets of ERK and RIPK3 kinases, thereby securely anchoring them in place. These findings underscore the development of promising modulators for ERK and RIPK3 kinases, suggesting their potential for future contributions to cancer treatments.